ClinConnect ClinConnect Logo
Search / Trial NCT04128306

Brain Areas of Time-To-Contact Perception: an Awake Surgery Study

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Oct 14, 2019

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Time To Contact Estimation Awake Brain Surgery Brain Tumor Cerebral Mapping

ClinConnect Summary

This clinical trial is studying how our brain perceives the time it takes for moving objects to reach us, which is an important skill we use in everyday life, like catching a ball or avoiding a moving vehicle. During brain surgery to remove a tumor, patients are temporarily woken up so that doctors can precisely locate the tumor and avoid damaging healthy brain tissue. While the patient is awake, researchers will conduct tests to understand which areas of the brain are involved in this perception.

To participate in this study, patients must have a brain tumor that does not affect their dominant hand and should be able to see well. They must also agree to the study terms and not have any eye movement disorders. The trial is open to all genders and includes a control group of healthy individuals who meet similar vision and health criteria. Participants can expect to be involved in the study during their surgery, where their brain activity will be monitored while they perform specific tasks. It's important to know that certain conditions, like tumors located in specific brain areas or serious neurological diseases, may exclude someone from participating.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • For the patients:
  • Brain tumor that does not affect the dominant hand motricity. The patient that have a tumor in an area targeted for a cortical stimulation will be automatically enrolled within the Pre-End group.
  • Who will agree with all terms and sign the experimental agreement
  • Correct or corrected vision, as allowed by the surgery constraints
  • With no known oculomotor abnormalities (list of exclusion in Annexe)
  • Affiliated to a social security system
  • For the control group:
  • Who will agree with all terms and sign the experimental agreement
  • Correct or corrected vision
  • With no known oculomotor abnormalities.
  • Affiliated to a social security system
  • Exclusion Criteria:
  • For the patients:
  • Brain tumor located in the occipital area
  • Legally protected patient, or with unknown ability to sign the experimental agreement, as determined by the medical team.
  • Medical background of neurological diseases of the central nervous system, as Parkinson, Alzheimer, stroke
  • Pregnancy
  • For the control group:
  • Legally protected patient, or with unknown ability to sign the experimental agreement, as determined by the medical team.
  • Medical background of neurological diseases of the central nervous system, as Parkinson, Alzheimer, stroke
  • Pregnancy

About University Hospital, Toulouse

The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.

Locations

Toulouse, , France

Patients applied

0 patients applied

Trial Officials

Franck-Emmanuel Roux, MD

Principal Investigator

University Hopsital Toulouse

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials